A Phase 2 multi-center, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimers Disease (US202)
A study for patients with mild to moderate Alzheimer's Disease using study drug T-817MA
Sponsor: Toyama Chemical Co., Ltd
Enrolling: Male and Female Patients
Study Length: 14 Months
Clinic Visits: 12
IRB Number: AAAN3252
U.S. Govt. ID: NCT02079909
Contact: Ruth Tejeda: 212-305-7661 / rbt41@columbia.edu
Additional Study Information: The purpose of this study is to determine whether an investigational drug, T-817MA, is safe and beneficial in delaying or altering the decline in memory and daily functioning when given to people with Alzheimer's disease. Participants will be given either an active study drug (T-817) or placebo (no active medication).
This study is closed
Investigator
Karen Bell, MD
Do You Qualify?
Do you have mild to moderate Alzheimer's disease and are taking donepezil or rivastigmine transdermal (on skin) system? Yes No
Are you living in an elderly community? Yes No
Have you been diagnosed with any significant cardiac issues? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Ruth Tejeda
rbt41@columbia.edu
212-305-7661
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE